禽传染性支气管炎GI-23型减毒活疫苗的实验室安全性与免疫原性评价
本研究依据欧洲药典Ph. Eur. 0442设计,评价基于Eg/1212B株的禽传染性支气管炎减毒活疫苗对鸡的安全性与效力。疫苗在SPF鸡连续传五代未返强,10倍 overdose无临床感染或疫苗相关死亡,单次接种可抵抗近期欧洲野毒株攻击,免疫 onset 21天、持续至56天,点眼保护率100%~85%,喷雾80%~85%。
要点
- 疫苗病毒在SPF鸡连续传五代无返强或毒力增强趋势。
- 10倍 overdose 接种后无鸡出现IBV临床感染或疫苗相关死亡。
- 单次接种免疫 onset 21天、持续至56天,点眼保护率100%~85%,喷雾80%~85%。
核心结论
- 安全性与效力数据确认正获益/风险平衡,该产品可作为控制禽传染性支气管炎GI-23相关肾致病性变异株的合适疫苗候选。
研究设计与样本
- 研究依据欧洲药典Ph. Eur. 0442设计,评价基于Eg/1212B株的减毒活疫苗用于鸡免疫接种。
- 在SPF鸡进行连续五代回传以评估返强,并比较接种组与对照组纤毛停滞评分和肾脏组织学病变。
- 以10倍 overdose 评估安全性,并以近期欧洲野生型IBV株攻击模型评估单次接种的保护力。
主要发现
- 疫苗病毒在SPF鸡连续五代回传后未显示返强或毒力增强倾向。
- 接种组与对照组的纤毛停滞评分及肾脏组织学病变相当。
- 10倍 overdose 接种后无鸡出现IBV感染临床体征或死于疫苗可归因原因。
- 单次接种即可在近期欧洲野生型IBV株攻击模型中保护鸡只,免疫 onset 为21天,免疫持续时间长达56天。
- 点眼个体接种保护率为100%~85%,喷雾群体接种保护率为85%~80%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avian infectious bronchitis virus (IBV) is responsible for a highly contagious disease that poses a significant threat to the poultry industry due to its high rates of evolution. The occurrence of vaccination failure can frequently be attributed to the emergence of novel strains that exhibit antigenic divergence from conventional vaccine strains. This study aims to evaluate the safety and efficacy of the Eg/1212B-based live attenuated virus vaccine indicated for immunization of chickens against nephropathogenic GI-23 variant strains reported globally. Studies were designed in compliance with European Pharmacopeia Ph. Eur. 0442. The attenuated vaccine virus did not exhibit any tendency to revert or increase in virulence after five back-passages in SPF chickens. Ciliostasis scores and kidney lesions (histology) were comparable between vaccinated and control birds. No chicken showed clinical signs of an infection with IBV or died from causes attributable to the vaccine after receiving a 10× overdose. A single vaccination was able to protect the birds in a challenge model with a recent European wild-type IBV strain. The study demonstrated an onset of immunity of 21 days and a duration of immunity lasting up to 56 days. Vaccination administered individually through the ocular route resulted in a protection rate of 100 % to 85 %, whereas mass application by spraying offered a protection rate of 85 % to 80 %. In conclusion, the safety and efficacy data confirm a positive benefit/risk balance, and the investigated product can be considered a suitable vaccine candidate for controlling avian infectious bronchitis nephropathogenic variant strains related to GI-23.
引用
- Kilany WH, Zain El-Abideen MA, Hisham I, et al. Laboratory safety and immunogenicity evaluation of live attenuated avian infectious bronchitis GI-23 virus vaccine. Vaccine. 2024. PMID: 39721355. doi:10.1016/j.vaccine.2024.126659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。